Novartis CDK4/6 inhibitor Kisqali approved for early breast cancer adjuvant therapy indication.

On May 14th, Novartis China announced that its breast cancer treatment product Kisqali has been approved by the National Medical Products Administration for a new indication - it can be used in combination with aromatase inhibitors as an adjuvant treatment for early-stage breast cancer patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative high-risk of recurrence.